Roche bets on the RNAi approach for obesity through $1bn Rona deal
The Swiss pharma giant now joins a growing list of big pharma and biotech players exploring the RNAi approach’s promise in treating obesity.
The Swiss pharma giant now joins a growing list of big pharma and biotech players exploring the RNAi approach’s promise in treating obesity.